@article{JTD16957,
author = {Pier Luigi Filosso and Enrico Ruffini and Paolo Solidoro and Matteo Roffinella and Paolo Olivo Lausi and Paraskevas Lyberis and Alberto Oliaro and Francesco Guerrera},
title = {Neuroendocrine tumors of the thymus},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {Suppl 15},
year = {2017},
keywords = {},
abstract = {Primary neuroendocrine tumors of the thymus (NETTs) are rare and biologically very aggressive neoplasms, usually located in the anterior mediastinal space. They are more frequently observed in males, in their fourth/fifth decades of life. In 50% of cases, NETTs are associated with endocrinopaties [Cushing’s syndrome, acromegaly or Multiple Endocrine Neoplasia-1 (MEN-1) syndrome]. NETTs very often present with invasion of the surrounding mediastinal anatomical structures. Surgery, even in advanced stages, is the mainstay of treatment: a compete resection through a median sternotomy or a combined access (sternotomy + thoracotomy) should be always attempted. Induction chemotherapy (± radiotherapy) is usually administered in advanced neoplasms, with the aim to achieve tumor shinkage, increasing, therefore, the chance to obtain a complete resection. Postoperative radiotherapy (± chemotherapy) is administered in case of invasive lesions, or incomplete resections. NETTs long-term outcome is poor, even in case of completely resected tumors, due to high risk of recurrence or distant metastases development. Prognosis mainly depends on tumor stage, invasivity, completness of resection, possible association with endocrinopaties and recurrence/distant metastases development.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/16957}
}